3 withdrawn. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
| Phase 3 | 3 | Withdrawn 3 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg - Hereditary Angioedema | Phase 2 / Phase 3 | Withdrawn | AO GENERIUM | 2021-12-01 | 2022-02-04 | |
| Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema ecallantide - Hereditary Angioedema (HAE) | Phase 2 / Phase 3 | Withdrawn | Shire | 2012-06-01 | 2021-05-18 | |
| Etanercept for the Treatment of Chronic Urticaria etanercept, placebo - Chronic Idiopathic Urticaria | Phase 2 / Phase 3 | Withdrawn | University of Utah | 2010-12-01 | 2015-06-02 |
Angioedemas, Hereditary (2) · Angioedema (1) · Chronic Urticaria (1) · Genetic Diseases, Inborn (1) · Hypersensitivity (1) · Immune System Diseases (1)
Hypersensitivity, Immediate (3) · Skin Diseases (3) · Skin Diseases, Vascular (3) · Skin and Connective Tissue Diseases (3) · Cardiovascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Hereditary Complement Deficiency Diseases (2) · Hypersensitivity (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Primary Immunodeficiency Diseases (2) · Vascular Diseases (2) · Angioedema (1) · Chronic Disease (1)
Complement C1 Inhibitor Protein (1) · Etanercept (1) · ecallantide (1)
AO GENERIUM (1) · Shire (1) · University of Utah (1)
Russia (1) · United States (1)
Christopher Hull, MD (1) · Oksana A. Markova, MD (1)